At the recent World Economic Forum in Davos, Google DeepMind's CEO Demis Hassabis stated that the first drugs designed with the help of artificial intelligence could begin clinical trials by 2025. Hassabis also heads Isomorphic Labs, a drug research company under DeepMind. He stated, "Our plan is to have some AI-designed drugs enter clinical trials by the end of this year."

Recently, Demis Hassabis, one of the founders of Google, revealed in an interview that his company Isomorphic Labs plans to begin a clinical trial for a drug developed using artificial intelligence (AI) by the end of the year. This news has drawn significant attention, particularly regarding its potential applications in oncology, cardiovascular diseases, and neurodegenerative disorders. Image credit: Image generated by AI, image licensed from Midjourney Isomorphic.

🧪 Drug Discovery Process: The article mentions that it takes an average of 6 years for a drug to go from discovery to clinical trial phase. 📈 AI Companies Claim: AI startups claim that their drug candidate compounds have shortened the time from discovery to clinical trials to under 10 years, with some individual cases taking only 30 months. 🧐 Caution is Advised: These claims lack independent third-party verification, as clinical trials are necessary to test their feasibility.

Neuralink is recruiting patients with quadriplegia and ALS for its first human trial. The purpose of the trial is to assess the safety and functionality of the brain-computer interface implantation tool, marking a crucial step in Neuralink's advancement of clinical applications for brain-computer interfaces.